Aquestive Therapeutics Stock Performance
| AQST Stock | USD 3.25 0.04 1.25% |
The firm shows a Beta (market volatility) of 1.11, which signifies a somewhat significant risk relative to the market. Aquestive Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Aquestive Therapeutics is expected to follow. At this point, Aquestive Therapeutics has a negative expected return of -0.0429%. Please make sure to confirm Aquestive Therapeutics' total risk alpha, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Aquestive Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Aquestive Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Aquestive Therapeutics is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return 1.25 | Five Day Return 11.3 | Year To Date Return (11.44) | Ten Year Return (79.75) | All Time Return (79.75) |
1 | Disposition of 56824 shares by Daniel Barber of Aquestive Therapeutics at 4.88 subject to Rule 16b-3 | 01/24/2025 |
2 | Acquisition by Cochran John of 25000 shares of Aquestive Therapeutics at 0.7132 subject to Rule 16b-3 | 02/10/2025 |
3 | Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 800 a.m.... | 02/20/2025 |
4 | Xencor Reports Q4 Loss, Tops Revenue Estimates | 02/27/2025 |
5 | Acquisition by Sherry Korczynski of 35000 shares of Aquestive Therapeutics at 2.65 subject to Rule 16b-3 | 02/28/2025 |
6 | Aquestive Therapeutics Inc Q4 2024 Everything You Need To Know Ahead Of Earnings | 03/04/2025 |
7 | What To Expect From Aquestive Therapeutics Inc Q4 2024 Earnings | 03/05/2025 |
8 | Aquestive Therapeutics Inc Q4 2024 Earnings Call Highlights Strategic Advances Amid ... | 03/07/2025 |
9 | Aquestive Therapeutics, Inc. Q4 2024 Earnings Call Transcript | 03/10/2025 |
10 | Acquisition by Stephen Wargacki of 65000 shares of Aquestive Therapeutics at 2.65 subject to Rule 16b-3 | 03/11/2025 |
| Begin Period Cash Flow | 23.9 M |
Aquestive |
Aquestive Therapeutics Relative Risk vs. Return Landscape
If you would invest 352.00 in Aquestive Therapeutics on December 24, 2024 and sell it today you would lose (27.00) from holding Aquestive Therapeutics or give up 7.67% of portfolio value over 90 days. Aquestive Therapeutics is currently does not generate positive expected returns and assumes 4.2666% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Aquestive, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aquestive Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aquestive Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aquestive Therapeutics, and traders can use it to determine the average amount a Aquestive Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0101
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AQST |
Estimated Market Risk
| 4.27 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Aquestive Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aquestive Therapeutics by adding Aquestive Therapeutics to a well-diversified portfolio.
Aquestive Therapeutics Fundamentals Growth
Aquestive Stock prices reflect investors' perceptions of the future prospects and financial health of Aquestive Therapeutics, and Aquestive Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aquestive Stock performance.
| Return On Asset | -0.24 | ||||
| Profit Margin | (0.77) % | ||||
| Operating Margin | (1.14) % | ||||
| Current Valuation | 285.32 M | ||||
| Shares Outstanding | 98.87 M | ||||
| Price To Earning | (1.90) X | ||||
| Price To Sales | 5.58 X | ||||
| Revenue | 57.56 M | ||||
| Gross Profit | 39.69 M | ||||
| EBITDA | (26.62 M) | ||||
| Net Income | (44.14 M) | ||||
| Cash And Equivalents | 17.7 M | ||||
| Cash Per Share | 0.33 X | ||||
| Total Debt | 38 M | ||||
| Debt To Equity | 468.20 % | ||||
| Current Ratio | 1.47 X | ||||
| Book Value Per Share | (0.66) X | ||||
| Cash Flow From Operations | (35.76 M) | ||||
| Earnings Per Share | (0.51) X | ||||
| Market Capitalization | 321.33 M | ||||
| Total Asset | 101.42 M | ||||
| Retained Earnings | (363.21 M) | ||||
| Working Capital | 69.36 M | ||||
| Current Asset | 38.38 M | ||||
| Current Liabilities | 17.95 M | ||||
About Aquestive Therapeutics Performance
Assessing Aquestive Therapeutics' fundamental ratios provides investors with valuable insights into Aquestive Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Aquestive Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 123.44 | 71.34 | |
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | 0.73 | 0.93 |
Things to note about Aquestive Therapeutics performance evaluation
Checking the ongoing alerts about Aquestive Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aquestive Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aquestive Therapeutics generated a negative expected return over the last 90 days | |
| Aquestive Therapeutics has high historical volatility and very poor performance | |
| Aquestive Therapeutics has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the previous year's revenue of 57.56 M. Net Loss for the year was (44.14 M) with profit before overhead, payroll, taxes, and interest of 39.69 M. | |
| Aquestive Therapeutics currently holds about 17.7 M in cash with (35.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33. | |
| Latest headline from insidermonkey.com: Aquestive Therapeutics, Inc. Q4 2024 Earnings Call Transcript |
- Analyzing Aquestive Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aquestive Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Aquestive Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aquestive Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aquestive Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aquestive Therapeutics' stock. These opinions can provide insight into Aquestive Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.